First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors

Inclusion Criteria:

* Advanced-stage solid tumor (metastatic or locally advanced and unresectable) with histologically confirmed diagnosis of CRC, NSCLC, GC, RCC, or HCC
* Measurable lesion(s) according to RECIST 1.1 criteria
* Performance status of ≤ 2 on the Eastern Cooperative Oncology Group (ECOG) scale.
* Ability to swallow capsules
* Received last chemotherapy, biologic, or investigational therapy at least 4 weeks prior to first dosing of study treatment
* Has received or is intolerant to all standard of care treatment options with known clinical benefit
* Life expectancy of more than 3 months
* Adequate hematological, hepatic and renal function
* For women of childbearing potential, a negative serum pregnancy test performed within 7 days prior to start of treatment

Exclusion Criteria:

* Received treatment within the last 28 days with a drug that has not received regulatory approval for any indication at the time of study entry
* Major surgery within the last 28 days prior to the first dose of investigational drug
* Prior radiation therapy within 14 days prior to study Cycle 1 Day 1 and/or persistence of radiation-related adverse effects.
* Concurrent treatment with any anticancer agent
* Currently taking either strong CYP inhibitors or inducers
* Known brain metastases, uncontrolled seizure disorder, or active neurologic disease
* Significant cardiovascular impairment
* Pregnant or nursing
* Known HIV infection, active hepatitis C and/or hepatitis B infection
* Known bleeding disorder or coagulopathy
* Active drug or alcohol abuse or history of alcohol or drug abuse during the last two years.
* Diagnosis of osteoporosis at the time of the screening
* Any history of retinal pathology including diabetic retinopathy, macular degeneration, or other retinal degenerative disease